^
Association details:
| Biomarker: | BCR-ABL1 T315L |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
Published date:
12/20/2020
Excerpt:
...a 77-year-old male with a diagnosis of Ph positive ALL resistant to ponatinib and carrying a rare threonine to leucine (T315L) mutation on BCR-ABL1 gene. The patient was treated with axitinib at 5 mg/twice daily as salvage therapy showing an immediate although transient benefit with an overall survival of 9.3 months.
DOI:
10.3390/ijms21249724
